|
|||||
|
|
Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer |
|
| Abstract: | Abstract Objective:To compare the costs of first-line treatment with panitumumab?+?FOLFOX in comparison to cetuximab?+?FOLFIRI among patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC) in the US. |
| Keywords: | Cost-minimization – Panitumumab – Cetuximab – FOLFOX – FOLFIRI – Colorectal cancer – First-line |